The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

In this study, we report the results of the epidemiological analysis of Clostridioides difficile ribotypes (RTs) and antimicrobial susceptibility testing. Most isolates were RT027, representing 73% (84/115) of isolates. No isolates with reduced susceptibility to fidaxomicin were found; howeve …

It’s possible that C diff could be a marker for frailty in geriatric patients.

Implications regarding how to properly treat patients with C. difficile infections based on data that have emerged since clinical practice guidelines were last updated.

Important factors to consider when selecting an appropriate therapy to treat C. difficile.

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.  

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.  

Although clostridioides difficile is the leading cause of health care-associated infection in the United States, there are currently only 2 antibiotics available for its treatment: vancomycin and fidaxomicin.

Clostridioides difficile is the leading cause of antibiotic-associated diarrhea but can also result in more serious, life-threatening conditions. The incidence of C. difficile infections in hospitals is increasing, both in frequency and severity, and antibiotic-resistant C. difficil …

CDI may complicate the course of IBD, however the presentation may not be typical. Therefore, all patients with worsening gastrointestinal symptoms should be evaluated for both CDI and IBD exacerbation. Providers should consider FMT for all patients with recurrent CDI as well as escalation of immuno …

Peer Exchange Coming Soon